Increased expression of plasminogen activator inhibitor-1 in R. rickettsii-infected endothelial cells

Thrombosis and Haemostasis

Volumn 75, Issue 4, 1996, Pages 600-606

  Shi, Rui Jin ^a   Simpson Haidaris, Patricia J ^a   Marder, Victor J ^a   Silverman, David J ^b   Sporn, Lee Ann ^a,c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFUR 35;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; ISOTOPE LABELING; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN INDUCTION; RICKETTSIA RICKETTSII; ROCKY MOUNTAIN SPOTTED FEVER;

EID: 0029986648     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650329     Document Type: Article

References (69)

1. Hattwick MA, O'Brien RJ, Hanson BF. Rocky Mountain spotted fever: Epidemiology of an increasing problem. Ann Intern Med 1976; 84: 732-9.
2. Hattwick MA, Retailliau H, O'Brien RJ, Slutzker M, Fontaine RE, Hanson B. Fatal Rocky Mountain spotted fever. JAMA 1978; 240; 1499-503.
3. Walker DH. Rocky Mountain spotted fever: A disease in need of microbiological concern. Clin Microbiol Revs 1989; 2: 227-40.
4. Rao AK, Schapira M, Clements ML, Niewiarowski B, Budzynski AZ, Schmaier AH, Harpel PC, Blackwelder WC, Scherrer JR, Sobel E, Colman RW. A prospective study of platelets and plasma proteolytic systems during early Rocky Mountain spotted fever. N Engl J Med 1988; 318: 1021-8.
5. Helmick CG, Bernard KW, D'Angelo LJ. Rocky Mountain spotted fever: Clinical, laboratory, and epidemiological features of 262 cases. J Infect Dis 1984; 150: 480-8.
6. Trigg JW Jr. Hypofibrinogenemia in Rocky Mountain spotted fever - Report of a case. New Engl J Med 1964; 270: 1042-4.
7. Kurnick JE, Malinow SH, Snyderman MC. Disseminated intravascular coagulation in Rocky Mountain spotted fever. Southern Med J 1974; 67: 623-5.
8. Deep WD, Schriever HG, Turner W. Defibrination syndrome in Rocky Mountain Spotted Fever. Va Med Monthly 1969; 96: 92-5.
9. Yoshikawa T, Tanaka KR, Guze LB. Infection and disseminated intravascular coagulation. Medicine 1971; 50: 237-57.
10. Walker TS. Rickettsial interactions with human endothelial cells in vitro: Adherence and entry. Infect Immun 1984, 44: 205-10.
11. Walker TS, Winkler HH. Penetration of cultured mouse fibroblasts (L cells) by Rickettsia prowazekii. Infect Immun 1978; 22: 200-8.
12. Winkler HH, Miller ET. Phospholipase A and the interaction of Rickettsia prowazekii and mouse fibroblasts (L-929 cells). Infect Immun 1982; 38: 109-13.
13. Walker DH, Firth WT, Ballard JG, Hegarty BC. Role of phospholipase-associated penetration mechanism in cell injury by Rickettsia rickettsii. Infect Immun 1983; 40: 840-2.
14. Silverman DJ, Santucci LA, Meyers N, Sekeyova Z. Penetration of host cells by Rickettsia rickettsii appears to be mediated by a phospholipase of rickettsial origin. Infect Immun 1992; 60: 2733-40.
15. Wisseman CL Jr, Edlinger EA, Waddell AD, Jones MR. Infection cycle of Rickettsia rickettsii in chicken embryo and L-929 cells in culture. Infect Immun 1976; 14: 1052-64.
16. Sporn LA, Haidaris PJ, Shi R-J, Nemerson Y, Silverman DJ, Marder VJ. Rickettsia rickettsii infection of cultured human endothelial cells induces tissue factor expression. Blood 1994; 83: 1527-34.
17. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA. Recombinant tumor necrosis factor induced procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin. Proc Natl Acad Sci USA 1986; 83 4533-7.
18. Nawroth P, Stern D. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-5.
19. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 1984; 160: 618-23.
20. Lydberg T, Galdal KS, Evensen SA, Prydz H. Cellular cooperation in endothelial cell thromboplastin synthesis. Br J Haematol 1983; 53: 85-95.
21. Colucci M, Balconi G, Lorenzet R, Pietra A, Locati D, Donati MB, Semeraro N. Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 1983; 73: 1893-7
22. Colucci M, Paramo J, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24.
23. Crutchley DJ, Conanan LB. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells. J Biol Chem 1986; 261: 154-9.
24. Hanss M, Collen D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by cultured human endothelial cells: modulation by thrombin, endotoxin, and histamine. J Lab Clin Med 1987; 109: 97-104.
25. Sawdey M, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction of lipopolysaccharide, tumor necrosis factor- and transforming growth factor-β. J Clin Invest 1991; 88: 1346-53.
26. Emeis JJ, Kooistra T. Interleukin 1 and lipopolysaccharide induce an inhibitor of tissue type plasminogen activator in vivo and in cultured endothelial cells. J Exp Med 1986; 163: 1260-6.
27. Bevilacqua MP, Schleef RR, Gimbrone MA Jr, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest 1986; 78: 587-91.
28. Garfinkel S, Brown S, Wessendorf JHM, Maciag T. Post-transcriptional regulation of interleukin 1α in various strains of young and senescent human umbilical vein endothelial cells. Proc Natl Acad Sci USA 1994; 91: 1559-63.
29. Dosne AM, Dubor F, Lutcher F, Parant M, Chedid L. Tumor necrosis factor (TNF) stimulates plasminogen activator inhibitor (PAI) production by endothelial cells and decreases blood fibrinolytic activity in the rat. Thromb Res 1988; 8: 115-22.
30. van den Berg EA, Sprengers ED, Jaye M, Burgess W, Maciag T, van Hinsbergh VWM. Regulation of plasminogen activator inhibitor-1 mRNA in human endothelial cells. Thromb Haemost 1988; 60: 63-7.
31. Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone MA Jr, Loskutoff DJ. Cytokine activation of vascular endothelium. J Biol Chem 1988; 263: 5797-803.
32. Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties - modulation of tissue factor, plasminogen activator inhibitor, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 1989; 264: 20705-13.
33. Gelehrter TD, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1986; 77: 165-9.
34. Dichek D, Quertermous T. Thrombin regulation of mRNA levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in cultured human umbilical vein endothelial cells. Blood 1989; 74: 222-8.
35. Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor β on the regulation of plasminogen activator in capillary endothelial cells. J Cell Biol 1987; 105: 957-63.
36. Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela D, Blasi F, Danø K. Transforming growth factor-β is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J 1987; 6: 1281-6.
37. Etingin OR, Hajjar DP, Hajjar KA, Harpel PC, Nachman RL. Lipoprotein(a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. J Biol Chem 1991; 266: 2459-65.
38. Santell L, Levin EG. Cyclic AMP potentiates phorbol ester stimulation of tissue plasminogen activator release and inhibits secretion of plasminogen activator inhibitor-1 from human endothelial cells. J Biol Chem 1988; 263: 16802-8.
39. Drancourt M, Alessi MC, Levy PY, Juhan-Vague I, Raoult D. Secretion of tissue-type plasminogen activator and plasminogen activator inhibitor by Rickettsia conorii and Rickettsia rickettsii infected cultured endothelial cells. Infect Immun 1990; 58: 2459-63.
40. Gimbrone MA Jr, Cotran RS, Folkman J. Human vascular endothelial cells in culture. Growth and DNA synthesis. J Cell Biol 1974; 60: 673-84.
41. Wagner DD, Olmsted JB, Marder VJ. Immunolocalization of von Willebrand protein in Weibel-Palade bodies of human endothelial cells. J Cell Biol 1982; 95: 355-60.
42. Silverman DJ, Santucci LA. Potential for free radical-induced lipid peroxidation as a cause of endothelial cell injury in Rocky Mountain spotted fever. Infect Immun 1988; 56: 3110-5.
43. Sporn LA, Shi R-J, Lawrence SO, Silverman DJ, Marder VJ. Rickettsia rickettsii infection of cultured endothelial cells induces release of large von Willebrand factor multimers from Weibel-Palade bodies. Blood 1991; 78: 2595-602.
44. Sprengers ED, Verheijen JH, van Hinsbergh VWM, and Emeis JJ. Evidence for presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Bioch Bioph Acta 1984; 801: 163-70.
45. Erickson LA, Lawrence DA, Loskutoff DJ. Reverse fibrin autography: A method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Analyt Biochem 1984; 137: 454-63.
46. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor plasminogen activator that can be activated by denaturants. J Biol Chem 1985, 260: 11581-7.
47. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond) 1970; 227: 680-5.
48. Simpson PJ. An improved method for mRNA isolation and characterization of in vitro translation products by Western blotting. Gene 1987; 56: 161-71.
49. Fourney RM, Miyakoshi J, Day RS III, Paterson MC. Northern blotting. Efficient RNA staining and transfer. Focus 1988; 10: 5-7.
50. Ny T, Sawdey M, Lawrence DA, Millan JL, Loskutoff DJ. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial cell-type plasminogen activator inhibitor. Proc Natl Acad Sci USA 1986; 83: 6776-80.
51. Edlund T, Ny T, Ranby M, Hedén LO, Palm G, Holmgren E, Josephson S. Isolation of cDNA sequences coding for a part of human tissue plasminogen activator. Proc Natl Acad Sci USA 1983; 80: 349-52.
52. Loskutoff DJ, Sawdy M, Mimuro J. Type 1 plasminogen activator inhibitor. In: Progress in Hemostasis and Thrombosis. Coller B, ed. W. B. Saunders, Philadelphia, PA 1989; pp 87-115.
53. Ginsburg D, Zeheb R, Yang AY, Rafferty UM, Andreasen PA, Nielsen L, Danø K, Lebo RV, Gelehrter TD. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest 1986; 78: 1673-80.
54. Bosma PJ, van den Berg EA, Kooistra T, Siemieniak DR, Slightom JL. Human plasminogen activator inhibitor-1 gene-promoter and structural gene nudeotide sequences. J Biol Chem 1988; 263: 9129-41.
55. Konkle VA, Ginsburg D. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression. J Clin Invest 1988; 82: 579-85.
56. Bok RA, Jacob HS, Balla J, Juckett M, Stella T, Shatos MA, Vercellotti GM. Herpes simplex virus decreases plasminogen activator inhibitor. Thromb Haemost 1993; 69: 253-8.
57. Philips M, Juul A, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochem Biophys Acta 1984; 802: 99-110.
58. Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture. Evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804-8.
59. Keeton N, Nguyen M, Loskutoff DJ. In vivo localization of type 1 plasminogen activator inhibitor (PAI-1) using in situ hybridization. Fibrinolysis 1990; 4: 52a (abstr).
60. Christ G, Seiffert D, Hufnagl P, Gessl A, Wojta J, Binder BR. Type 1 plasminogen activator inhibitor synthesis of endothelial cells is downregulated by smooth muscle cells. Blood 1993; 81: 1277-83.
61. Juhan-Vague I, Alessi MC, Joly P, Thirion X, Vague P, DeClerk PJ, Serradimigni A, Collen D. Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response. Arteriosclerosis 1989; 9: 362-7.
62. Hamsten A, De Faire Y, Walldius G, Dahlen G, Szamosi A, Landou C. Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
63. Colucci M, Paramo JA, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1985; 75: 818-24.
64. Engebretsen LF, Kierulf P, Brandizaeg P. Extreme plasminogen activator inhibitor and endotoxin values in patients with meningococcal disease. Thromb Res 1986; 42: 713-6.
65. Pralong G, Calandra T, Glauser MP, Schellekens J, Verhoef J, Bachmann F, Kruithof EKO. Plasminogen activator inhibitor-1: A new prognostic marker in septic shock. Thromb Haemost 1989; 61: 459-62.
66. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
67. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EKO. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arteriosclerosis and Thrombosis 1993; 13: 1090-9.
68. Chomiki N, Henry M, Alessi MC, Anfosso F, Juhan-Vague I. Plasminogen activator inhibitor-1 expresssion in human liver and healthy or atherosclerotic vessel walls. Thromb Haemost 1994; 72: 44-53.
69. Lang IM, Marsh JJ, Olman MA, Moser KM, Loskutoff DJ, Schleef RR. Expression of type-1 plasminogen activator inhibitor in chronic pulmonary thromboemboli. Circulation 1994; 89: 2715-21.